http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Transgene and NEC Present New Data Confirming Clinical Proof of Principle for Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at SITC 2024
-
Transgene and NEC Present New Data Confirming Clinical Proof of Principle for Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at SITC 2024
-
Transgene and BioInvent’s Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase I/IIa Trial in Solid Tumors that Failed Previous Treatments
-
Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024
-
Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024
-
Transgene, NEC, and BostonGene Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050
-
Transgene and NEC Extend their Collaboration to Continue Joint Clinical Development of Neoantigen Cancer Vaccine TG4050
-
Transgene Announces Upcoming Investor Meetings
-
Transgene Strengthens its Leadership Team to Accelerate its Growth Strategy
-
Transgene Reports Business Update and Q3 2023 Financial Position
-
Transgene and BioInvent - First Patient Treated in Part B of Phase I Trial Assessing the Novel Oncolytic Virus BT-001 in Combination With KEYTRUDA® (pembrolizumab)
-
Transgene Advances Its Innovative Immunotherapy Pipeline and Extends Financial Visibility Until the End of 2024
-
Transgene Announces Upcoming Investor Meetings
-
Transgene Receives $15.3 Million from the Sale of Securities Held for Sale
-
Transgene and NEC Present New Data on TG4050, an Individualized Cancer Vaccine, Showing it Induces Specific Immune Responses against Head and Neck Carcinoma at ASCO 2023
-
Transgene Presents Immunological Data Demonstrating that TG4001, a Novel Therapeutic Cancer Vaccine, Can Induce T-cell Responses Against HPV16 Antigens in the Ongoing Phase II Trial at ASCO 2023
-
Transgene to Present Data on its Two Therapeutic Cancer Vaccines at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Transgene and BioInvent Report Positive Phase Ia Data on Oncolytic Virus BT-001 in Solid Tumors
-
Transgene provides business update and Q1 2023 financial position
-
Transgene - First Patient Dosed in Phase I Trial Evaluating TG6050, a Novel IL-12-Armed Oncolytic Virus Administered Intravenously, in Non-Small Cell Lung Cancer
-
Transgene’s Combined General Meeting of May 5, 2023
-
Transgene Announces New Leadership Structure to Accelerate the Development of its Innovative Immunotherapy Portfolio
-
New Data Showing that Transgene and NEC’s Individualized Cancer Vaccine TG4050 Induces Strong and Specific Immune Responses against Tumors Presented at AACR 2023
-
Transgene - Preclinical Results Showing TG6050, a Novel Oncolytic Virus, induces Tumor Regression by Activating Innate and Adaptive immune responses presented at AACR
-
Transgene’s Board of Directors Proposes the Appointment of Carol Stuckley, MBA, as New Independent Director
-
Transgene: Availability of Preparatory Documents for the Combined General Meeting of May 5, 2023
-
Transgene to Host KOL Webinar on TG4050: an Individualized Cancer Vaccine for the Treatment of HPV-Negative Head & Neck Cancers
-
Transgene Announces Upcoming Investor Meetings
-
Transgene: 2022 Full-year Results and Business Update
-
Transgene to Present Multiple Posters Highlighting the Potential of its Exciting Immunotherapy Pipeline at AACR 2023
-
Transgene Appoints John C. Bell and Pedro Romero as Key Scientific Advisors
-
Transgene Receives Approval to Start a Phase I Trial of TG6050, a Novel IL-12-Armed Oncolytic Virus Given by Intravenous Administration
-
Transgene Announces Financial Calendar for 2023
-
Transgene Announces Upcoming Investor Meetings
-
Transgene and BioInvent Joint Paper on BT-001 Wins JITC “Best Oncolytic and Local Immunotherapy Paper” Award for 2022
-
Transgene Reports Business Update And Q3 2022 Financial Position
-
Transgene Announces Positive Interim Analysis Results of Phase II Trial Evaluating TG4001 + Avelumab vs Avelumab in HPV-Positive Anogenital Cancers
-
R&D Day: Presentations to Highlight Transgene’s Competitive Positioning, Capabilities to Engineer Novel Immunotherapies for Patients with Cancer, and Update on Initial Clinical Data
-
Transgene Confirms the Potential of the Intravenous Route of its Invir.IO™ Oncolytic Viruses against Solid Tumors with TG6002 Phase I Data Presented at ESMO Congress 2022
-
Positive Readouts for Transgene’s Clinical Stage Candidates Generated by its Two Innovative Platforms, with Further Clinical Data Expected in the Second Half of 2022
-
Transgene Announces Upcoming Investor Meetings
-
Transgene and BioInvent Announce Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate BT-001 in Combination with KEYTRUDA®
-
Transgene and BioInvent Announce Positive Progress for BT-001
-
Transgene Presented Additional Phase I Data with TG4050 (myvac® platform) at ASCO 2022
-
Transgene to Present Updated Positive Preliminary Data from the Phase I Clinical Trials with TG4050 (myvac® platform) at ASCO 2022
-
Transgene’s Combined General Meeting of May 25, 2022
-
Transgene Announces Upcoming Investor Meetings
-
Transgene: Q1 2022 Financial Position and Business Update
-
Transgene to Present New Positive Preliminary Phase I Clinical Data at AACR 2022, Reinforcing the Potential of TG4050
-
Transgene: Availability of Preparatory Documents for the Combined General Meeting of May 25, 2022
